Xarelto And Eylea Keep Bayer Buoyant
Despite Shadow Cast By Roundup Lawsuits
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
You may also be interested in...
New safety concerns over Novartis's anti-VEGF eye injection drug will likely cut its uptake and reduce its competitive threat to Bayer and Regeneron's VEGF inhibitor Eylea.
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.